Literature DB >> 31231438

Quantitative Imaging of Alpha-Emitting Therapeutic Radiopharmaceuticals.

Youngho Seo1,2,3,4,5,6.   

Abstract

Targeted alpha therapy (TAT) is an active area of drug development as a highly specific and highly potent therapeutic modality that can be applied to many types of late-stage cancers. In order to properly evaluate its safety and efficacy, understanding biokinetics of alpha-emitting radiopharmaceuticals is essential. Quantitative imaging of alpha-emitting radiopharmaceuticals is often possible via imaging of gammas and positrons produced during complex decay chains of these radionuclides. Analysis of the complex decay chains for alpha-emitting radionuclides (Tb-149, At-211, Bi-212 (decayed from Pb-212), Bi-213, Ra-223, Ac-225, and Th-227) with relevance to imageable signals is attempted in this mini-review article. Gamma camera imaging, single-photon emission computed tomography, positron emission tomography, bremsstrahlung radiation imaging, Cerenkov luminescence imaging, and Compton cameras are briefly discussed as modalities for imaging alpha-emitting radiopharmaceuticals.

Entities:  

Keywords:  Alpha-emitting radionuclide; Compton camera; PET; Quantitative imaging; SPECT; Targeted alpha therapy

Year:  2019        PMID: 31231438      PMCID: PMC6554362          DOI: 10.1007/s13139-019-00589-8

Source DB:  PubMed          Journal:  Nucl Med Mol Imaging        ISSN: 1869-3474


  33 in total

1.  Cellular dose conversion factors for alpha-particle--emitting radionuclides of interest in radionuclide therapy.

Authors:  K A Hamacher; R B Den; E I Den; G Sgouros
Journal:  J Nucl Med       Date:  2001-08       Impact factor: 10.057

2.  First in vivo evaluation of liposome-encapsulated 223Ra as a potential alpha-particle-emitting cancer therapeutic agent.

Authors:  Thora J Jonasdottir; Darrell R Fisher; Jørgen Borrebaek; Oyvind S Bruland; Roy H Larsen
Journal:  Anticancer Res       Date:  2006 Jul-Aug       Impact factor: 2.480

3.  Evaluation of quantitative planar 90Y bremsstrahlung whole-body imaging.

Authors:  D Minarik; M Ljungberg; P Segars; K Sjögreen Gleisner
Journal:  Phys Med Biol       Date:  2009-09-17       Impact factor: 3.609

4.  Pharmacokinetics and dosimetry of an alpha-particle emitter labeled antibody: 213Bi-HuM195 (anti-CD33) in patients with leukemia.

Authors:  G Sgouros; A M Ballangrud; J G Jurcic; M R McDevitt; J L Humm; Y E Erdi; B M Mehta; R D Finn; S M Larson; D A Scheinberg
Journal:  J Nucl Med       Date:  1999-11       Impact factor: 10.057

5.  A kit method for the high level synthesis of [211At]MABG.

Authors:  Ganesan Vaidyanathan; Donna J Affleck; Kevin L Alston; Xiao-Guang Zhao; Marc Hens; Duncan H Hunter; John Babich; Michael R Zalutsky
Journal:  Bioorg Med Chem       Date:  2007-03-12       Impact factor: 3.641

6.  Imaging hNET reporter gene expression with 124I-MIBG.

Authors:  Maxim A Moroz; Inna Serganova; Pat Zanzonico; Ludmila Ageyeva; Tatiana Beresten; Ekaterina Dyomina; Eva Burnazi; Ronald D Finn; Michael Doubrovin; Ronald G Blasberg
Journal:  J Nucl Med       Date:  2007-05       Impact factor: 10.057

7.  Pharmacokinetics, dosimetry, and toxicity of the targetable atomic generator, 225Ac-HuM195, in nonhuman primates.

Authors:  Matthias Miederer; Michael R McDevitt; George Sgouros; Kim Kramer; Nai-Kong V Cheung; David A Scheinberg
Journal:  J Nucl Med       Date:  2004-01       Impact factor: 10.057

8.  Targeted alpha therapy in vivo: direct evidence for single cancer cell kill using 149Tb-rituximab.

Authors:  G-J Beyer; M Miederer; S Vranjes-Durić; J J Comor; G Künzi; O Hartley; R Senekowitsch-Schmidtke; D Soloviev; F Buchegger
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-01-14       Impact factor: 9.236

9.  Treatment planning for 131I-mIBG radiotherapy of neural crest tumours using 124I-mIBG positron emission tomography.

Authors:  R J Ott; D Tait; M A Flower; J W Babich; R M Lambrecht
Journal:  Br J Radiol       Date:  1992-09       Impact factor: 3.039

10.  Engineered liposomes for potential alpha-particle therapy of metastatic cancer.

Authors:  Stavroula Sofou; James L Thomas; Hung-yin Lin; Michael R McDevitt; David A Scheinberg; George Sgouros
Journal:  J Nucl Med       Date:  2004-02       Impact factor: 10.057

View more
  1 in total

1.  Quantitative SPECT/CT imaging of lead-212: a phantom study.

Authors:  Monika Kvassheim; Mona-Elisabeth R Revheim; Caroline Stokke
Journal:  EJNMMI Phys       Date:  2022-08-04
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.